Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations

A high proportion of patients with lower-risk del(5q) myelodysplastic syndromes will respond to treatment with lenalidomide. The median duration of transfusion-independence is 2 years with some long-lasting responses, but almost 40% of patients progress to acute leukemia by 5 years after starting tr...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Haematologica
Glavni autori: Scharenberg, Christian, Giai, Valentina, Pellagatti, Andrea, Saft, Leonie, Dimitriou, Marios, Jansson, Monika, Jädersten, Martin, Grandien, Alf, Douagi, Iyadh, Neuberg, Donna S., LeBlanc, Katarina, Boultwood, Jacqueline, Karimi, Mohsen, Jacobsen, Sten Eirik W., Woll, Petter S., Hellström-Lindberg, Eva
Format: Artigo
Jezik:Inglês
Izdano: Ferrata Storti Foundation 2017
Teme:
Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5394951/
https://ncbi.nlm.nih.gov/pubmed/27884971
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2016.152025
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items